Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
- PMID: 17679671
- DOI: 10.1212/01.wnl.0000267885.47092.40
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
Abstract
Background: Late infantile neuronal ceroid lipofuscinosis (LINCL) is associated with progressive degeneration of the brain and retina starting in early childhood.
Methods: Thirty-two individual neurologic, ophthalmologic, and CNS imaging (MRI and MRS) assessments of 18 children with LINCL were analyzed. Disease severity was followed by two rating scales, one previously established but modified to solely assess the brain and exclude the retinal disease (modified Hamburg LINCL scale), and a newly developed scale, with expanded evaluation of the CNS impairment (Weill Cornell LINCL scale).
Results: For the 18 children, the Weill Cornell scale yielded a closer correlation with both age and time since initial clinical manifestation of the disease than did the modified Hamburg scale. There were no significant differences as a function of age or time since initial manifestation of the disease in the rating scales among the most frequent CLN2 mutations (G3556C, 56% of all alleles or C3670T, 22% of all alleles). Measurements of cortical MRS N-acetyl-aspartate content, MRI ventricular, gray matter and white matter volume, and cortical apparent diffusion coefficient correlated to a variable degree with the age of the children and the time since initial clinical manifestation of the disease. All imaging measurements correlated better with the Weill Cornell CNS scale compared to the modified Hamburg LINCL scale.
Conclusion: The data suggest that the Weill Cornell late infantile neuronal ceroid lipofuscinosis (LINCL) scale, together with several of the MRI measurements, may be useful in the assessment of severity and progression of LINCL and for the evaluation of novel therapeutic strategies.
Trial registration: ClinicalTrials.gov NCT00151268.
Comment in
-
Imaging of late infantile neuronal ceroid lipofuscinosis: a clinical rating scale.Neurology. 2007 Aug 7;69(6):503-4. doi: 10.1212/01.wnl.0000269663.23404.c5. Neurology. 2007. PMID: 17679667 No abstract available.
Similar articles
-
Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.Am J Med Genet. 2002 Nov 1;112(4):347-54. doi: 10.1002/ajmg.10660. Am J Med Genet. 2002. PMID: 12376936
-
Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.Pediatr Neurol. 2009 Oct;41(4):297-300. doi: 10.1016/j.pediatrneurol.2009.04.022. Pediatr Neurol. 2009. PMID: 19748052
-
R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis.Croat Med J. 2003 Aug;44(4):489-93. Croat Med J. 2003. PMID: 12950156
-
Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation.Seizure. 2019 Jul;69:180-185. doi: 10.1016/j.seizure.2018.08.027. Epub 2018 Sep 2. Seizure. 2019. PMID: 31059981
-
Neuronal ceroid lipofuscinoses and possible pathogenic mechanism.Mol Genet Metab. 2000 Sep-Oct;71(1-2):195-206. doi: 10.1006/mgme.2000.3057. Mol Genet Metab. 2000. PMID: 11001811 Review.
Cited by
-
Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease Progression.AJNR Am J Neuroradiol. 2016 Oct;37(10):1938-1943. doi: 10.3174/ajnr.A4816. Epub 2016 May 26. AJNR Am J Neuroradiol. 2016. PMID: 27231226 Free PMC article.
-
Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging.AJNR Am J Neuroradiol. 2013 Apr;34(4):884-9. doi: 10.3174/ajnr.A3297. Epub 2012 Oct 4. AJNR Am J Neuroradiol. 2013. PMID: 23042927 Free PMC article.
-
Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease.Hum Gene Ther. 2024 Jan;36(1-2):28-35. doi: 10.1089/hum.2024.182. Epub 2025 Jan 2. Hum Gene Ther. 2024. PMID: 39745261
-
Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.Exp Neurol. 2008 Sep;213(1):18-27. doi: 10.1016/j.expneurol.2008.04.022. Epub 2008 Apr 30. Exp Neurol. 2008. PMID: 18639872 Free PMC article.
-
Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.Front Neurol. 2022 Feb 8;13:785841. doi: 10.3389/fneur.2022.785841. eCollection 2022. Front Neurol. 2022. PMID: 35211079 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical